AExcellent

Gilead Sciences, Inc.(GILD)

A

Financial data as of Dec 31, 2025Improving · Healthcare

FCF Margin32.1%Free Cash Flow / Revenue
Cash Conversion117.7%Operating CF / Net Income
Free Cash Flow$9.5B
Revenue$29.4B
Net Cash-$17.4BNet debt position
Debt / FCF2.6xManageable debt load
Current Ratio1.55Adequate short-term liquidity
YoY FCF Growth+10.4%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseA
+0.5Healthy FCF margin with manageable debt (32.1%, 2.6x)
+0.5Modest YoY FCF growth (10.4% YoY)
FinalA

Analysis Summary

Strengths

  • Exceptional FCF margin (32.1%)
  • Excellent cash conversion (118%)
  • FCF trend is improving

Concerns

  • Net debt position ($17.4B) — 2.6x FCF, manageable

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin32.1%
Net Margin28.9%
Operating CF Margin34.0%
CapEx Ratio1.9%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash-$17.4BNet debt position
Debt / FCF2.6xManageable debt load
Current Ratio1.55Strong liquidity
Debt / Equity1.10Moderate leverage

Quarterly FCF Trend

+10.4% YoYImproving (+10.4%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameGilead Sciences, Inc.
SectorHealthcare
Free Cash Flow$9.5B
Revenue$29.4B
Net Income$8.5B
Operating Cash Flow$10.0B
Capital Expenditure$563.0M
FCF Margin32.1%
Cash Conversion Rate117.7%
Net Margin28.9%
Total Debt$24.9B
Total Cash$7.6B
Net Cash-$17.4B
Current Ratio1.55
Debt / Equity1.10
Debt / FCF2.6x
YoY FCF Growth+10.4%
Positive Quarters5 of 5
Trend DirectionImproving
Report DateDec 31, 2025
GradeA
Data SourceYahoo Finance